Sr Manager - Software Engineering

Shashanka Muppaneni named Danaher Chief Strategy Officer. September 28, 2026 Shashanka Muppaneni has been appointed SVP and Chief Strategy Officer at Danaher, while Brad Gray will step down as SVP of Strategic Development Life sciences and diagnostics company Danaher has announced changes to its strategy leadership team as it prepares for a broader transition at the top of the business. Effective 1 October 2026, Shashanka Muppaneni will become SVP and Chief Strategy Officer, moving from his current role as Group Vice President of Strategy and Business Development for Danaher's Diagnostics platform. The appointment comes as Julie Sawyer Montgomery prepares to take over as Danaher's President and CEO on the same date. Julie, who has led the company's Diagnostics platform, has played a key role in its growth, with the business increasing from approximately US$6bn in revenue in 2017 to around US$11bn in 2025. Julie says Shashanka "pairs sharp strategic thinking with a pragmatic, results-oriented approach," adding that he has demonstrated an ability to align strategy with business execution, deliver strategic M&A and build partnerships across Danaher's businesses. "He will be a strong partner as we accelerate Danaher's strategy and M&A agenda in the years ahead," she says. Danaher generated US$24.6bn in revenue in 2025 and operates across biotechnology, diagnostics and life sciences. Its portfolio includes businesses such as Cytiva, Beckman Coulter, Cepheid, Leica Biosystems and Masimo, spanning drug development, biomanufacturing, diagnostics and patient monitoring. Deep strategic and healthcare experience. Shashanka brings almost two decades of experience across strategy, healthcare and life sciences to his new role. He began his career in finance and strategy-oriented positions at Thomson Reuters and Microsoft before moving into healthcare-focused roles at Smiths Group and Upsher-Smith Laboratories. Danaher: Key Facts * US$24.6bn - Danaher's full-year revenue in 2025. * US$10bn - Annual revenue of Danaher's Diagnostics business in 2025. * US$9.9bn - Value of Danaher's 2026 acquisition of Masimo. * 1 October 2026 - Shashanka Muppaneni becomes Chief Strategy Officer. * 2024 - Year Shashanka joined Danaher's Diagnostics business. He subsequently held two positions at Boston Consulting Group, including Managing Director and Partner, as well as roles with life sciences companies including Illumina and Seer. Shashanka joined Danaher in 2024 to lead Strategy and Business Development for the Diagnostics platform, where his remit included strategic planning and M&A. His tenure has included Danaher's acquisition of Masimo, a specialty diagnostics and patient monitoring company. Danaher completed the US$10bn transaction in June 2026, adding Masimo as a standalone operating company within its Diagnostics segment. His experience in healthcare strategy and transactions is likely to be particularly relevant as Danaher continues to reshape its portfolio and identify opportunities for growth. Brad Gray to step down. Shashanka's appointment coincides with the departure of Brad Gray, Danaher's current SVP of Strategic Development. Brad has played a leading role in streamlining Danaher's strategy and M&A approach and supporting the deployment of more than US$10bn in capital since he joined in 2024. On LinkedIn, following the announcement of his departure, Brad writes: "These past two years shaping Danaher's strategy and M&A agenda have been amazing. I am proud of what our BD and Strategy teams accomplished together, from acquiring Masimo to laying out Danaher's enterprise strategy for the future. Thank you to this amazing team for the trust, partnership and hard work." He will remain with the company in an advisory capacity until March 2027. "I am proud of what our BD and Strategy teams accomplished together, from acquiring Masimo to laying out Danaher's enterprise strategy for the future. " Brad GrayOutgoing SVP of Strategic Development at Danaher Danaher prepares for leadership transition. The changes to Danaher's strategy leadership come as the company prepares for a broader executive transition. Julie will become President and CEO on 1 October 2026, succeeding Rainer Blair, who has led the company since 2020. Rainer will retire from the role and remain with Danaher as a senior adviser until 31 March 2027 to support the transition. Danaher has also announced that Heathre Moler will become Chief Human Resources Officer from 1 October 2026. The leadership changes come as Danaher enters its next phase of growth following a strong 2025. The company reported full-year revenue of US$24.6bn, up 3% year-on-year, while its acquisition strategy remains an important component of portfolio development. With Shashanka taking responsibility for corporate strategy and M&A, Danaher's leadership team will be tasked with building on that momentum while continuing to identify opportunities across its biotechnology, life sciences and diagnostics businesses. Key Danaher partners. CEO: Joe Kiani | HQ: Irvine, California Masimo develops non-invasive patient monitoring technologies, including pulse oximetry, sensors and connectivity platforms. Danaher completed its US$9.9bn acquisition in June 2026, making Masimo a wholly owned subsidiary within its Diagnostics segment while retaining the Masimo brand and standalone operating structure. AstraZeneca CEO: Pascal Soriot | HQ: Cambridge, UK AstraZeneca is a global biopharmaceutical company focused on oncology, rare diseases and biopharmaceuticals. In 2025, it partnered with Danaher to develop and commercialise novel diagnostics for precision medicine, initially focusing on digital and computational pathology and AI-assisted algorithms through Danaher's Leica Biosystems. The collaboration aims to improve identification of patients most likely to benefit from targeted therapies. Innovaccer CEO: Abhinav Shashank | HQ: San Francisco, California Innovaccer is a healthcare AI and data company providing platforms designed to connect healthcare data and support clinical decision-making. Danaher announced an investment partnership with Innovaccer in January 2025, combining Danaher's diagnostics expertise with Innovaccer's data and AI capabilities to advance diagnostic and clinical AI solutions. Executives. * Brad Gray SVP, Strategic Development * Julie Sawyer Montgomery President * Shashanka Muppaneni Chief Strategy Officer Company Portals

MaxCyte appoints Sidharth Kapileshwar as Chief Corporate Development Officer. September 23, 2026 08:05 ET | Source: MaxCyte, Inc ROCKVILLE, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) - MaxCyte, Inc. (Nasdaq: MXCT), a leading cell engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it has appointed Sidharth Kapileshwar as Chief Corporate Development Officer. "Sidharth has a proven track record of building and scaling corporate development functions inside some of the largest healthcare companies in the world. He knows firsthand what it takes to translate strategy into growth," said Maher Masoud, President and Chief Executive Officer. "I am confident that Sidharth's expertise will support MaxCyte's next chapter of growth." Mr. Kapileshwar joins MaxCyte from Danaher Corporation, where he most recently served as Vice President of Innovation for the company's Life Sciences Platform, leading enterprise-wide innovation programs. Over nearly 25 years, he has held corporate development, strategy, innovation, and M&A leadership roles at global life sciences and technology companies, including GE Healthcare, Beckman Coulter, and Halma plc. Mr. Kapileshwar holds a Master of Science in Engineering from The Ohio State University, an MBA from the University of Chicago Booth School of Business, and a Bachelor of Technology in Engineering from the Indian Institute of Technology Bombay. "MaxCyte has been an early pioneer in applying flow electroporation at clinical and commercial scale for cell and gene therapies, and its technologies are foundational to where the field is headed. That's exactly the kind of opportunity I want to help build at MaxCyte," said Sidharth Kapileshwar. "I've spent my career helping large, global organizations sharpen their strategies and execute their next phase of growth, and I'm excited to bring that same momentum to MaxCyte." About MaxCyte At MaxCyte(R), we are committed to building better cells together. As a leading cell-engineering company, we are driving the discovery, development and commercialization of next-generation cell therapies. Our best-in-class Flow Electroporation(R) technology and SeQure DX(TM) gene editing risk assessment services enable precise, efficient and scalable cell engineering. Supported by expert scientific, technical and regulatory guidance, our platform empowers researchers from around the world to engineer diverse cell types and payloads, accelerating the development of safe and effective treatments for human health. For more than 25 years, we've been advancing cell engineering, shaping the future of medicine. Learn more at maxcyte.com and follow us on X and LinkedIn. MaxCyte Contacts: Investor Relations Gilmartin Group Erik Abdow [email protected] Media Contact Oak Street Communications Kristen White +1 415-608-6060 [email protected]

Cardinal Health shares rose over 10% year-to-date but dropped more than 8% since early September. Jim Cramer attributed the decline to investor rotation into AI stocks rather than weak performance, calling the sell-off "stupid" given the company's strong quarterly results. Cardinal Health's fiscal fourth quarter earnings beat analyst estimates with profit per share of $2.91 and full-year guidance of $12.40 to $12.60 exceeding the $12.04 estimate. The pharmaceutical business grew revenue 6% annually to $55.4 billion, driven by demand for branded and specialty drugs. However, Q4 revenue of $63.67 billion missed analyst estimates of $65.03 billion. Management cautioned investors about normalisation ahead, particularly in specialty growth rates. By comparison, Danaher shares fell over 7% year-to-date after deferring $100 million in revenue and cutting its full-year revenue growth guidance.